<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Biopharma SERVICES

Biomarker discovery solutions

Working alongside our biopharmaceutical partners, we employ personalized and integrated approaches to uncover new solutions to diagnostic challenges with industry-leading expertise in blood-based testing.

Maximize your biomarker data from blood

Our diagnostic solutions leverage both genomics and proteomics to uncover comprehensive insights about the tumor biology and patient’s immune response to therapeutics in clinical development. We take a technology agnostic approach for blood-based biomarker discovery to ensure we provide the necessary solutions to fulfill your needs.

MALDI-ToF Mass Spectrometry

  • VeriStrat® Test
  • ImmunoStrat® Protein Signatures
  • Lung Cancer Risk of Recurrence Test
  • Biological Pathway Protein Score
  • Custom Signature Discovery
LEARN MORE ABOUT MALDI

Liquid Chromatography Mass Spectrometry

  • Nodify XL2® Lung Nodule Test
  • Lung Cancer Protein Panel
  • Alzheimer’s Protein Panel
  • Custom LC-MRM-MS Protein Panel
  • Unbiased DIA LC-MS/MS
  • Direct Neoantigen Characterization
LEARN MORE ABOUT LC-MS

Enzyme-Linked Immunosorbent Assay

    • Nodify CDT™ Lung Nodule Test
    • Platelia SARS-CoV-2 Total Ab Test
    • Custom ELISA Assay
LEARN MORE ABOUT ELISA

Droplet Digital™ PCR

  • GeneStrat® Test
    EGFR | EML4-ALK | ROS-1 | RET | KRAS | BRAF
  • Bio-Rad SARS-CoV-2 ddPCR Test
  • PD-L1 Expression Assay
  • Microsatellite Instability Assay
  • Custom Assay
LEARN MORE ABOUT DDPCR

Next Generation Sequencing

  • Pan-Cancer Cell-Free Assay
  • Cancer-Specific Assays (lung, breast, colon, myeloid, pediatric)
  • Tumor Mutation Burden Assay
  • Immune Response Assay
  • Immune Repertoire for TCR Beta Assay
Learn more about NGS

Biomarker Discovery Solution Process

Our biomarker discovery projects include discovering novel biomarker tests with our proprietary artificial intelligence platform, developing assays for known biological targets, retrospectively gathering insights from clinical studies, and prospectively enrolling patients into clinical trials. We follow a simple biomarker evaluation process to ensure our diagnostic tests are CDx-ready.

 

graphic

We provide end-to-end diagnostic solutions from initial biomarker discovery to commercialization through companion diagnostic partnering.

Our Approach to CDx Partnering

Contact our biopharma services team to learn more about our capabilities to be your biomarker discovery partner

Contact us